<DOC>
	<DOCNO>NCT02772003</DOCNO>
	<brief_summary>The purpose study determine whether INO-8000 alone combination INO-9012 ( IL-12 ) safe induces HCV-specific immune response .</brief_summary>
	<brief_title>Trial Therapeutic DNA Vaccine Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Presence chronic HCV infection . Age ≥18 year . Willingness use adequate contraception avoid pregnancy impregnation duration study participation . Willingness avoid excessive use alcohol study . Willingness provide blood sample research test specify protocol . Ability understand willingness sign write informed consent document . Serum plasma HCV RNA level ≥ 10,000 IU/mL . Screening HCV genotype , demonstrate genotype 1 . Alpha feto protein ( AFP ) level within normal institutional limit judge clinically significant investigator . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Screening laboratory value ( serum chemistry , hematology , prothrombin time ( PT ) ( International Normalized Ratio ( INR ) ) /Activated Partial Thromboplastin Time ( aPTT ) , creatine phosphokinase ( CPK ) ) within institutional normal range judge clinically significant physician medical monitor . 12lead electrocardiogram ( ECG ) show normal heart rhythm judge clinically significant physician medical monitor . Failure previous HCV therapy . HIV infection . Any previous treatment HCV ≤ 6 month prior registration . Other uncontrolled immunecompromising illness Autoimmune disorder , transplant recipient , immunosuppression include concurrent condition require use immunosuppressive/ immunomodulating agent . Ongoing HBV infection . Documented evidence fibrosis cirrhosis ( Metavir 2 , 3 , 4 ) subject significant extrahepatic manifestation hepatitis C ( cryoglobulinemia symptom evidence endorgan manifestation , renal disease , type 2 diabetes , porphyria cutanea tarda . Other known cause significant liver disease include chronic acute hepatitis B , acute hepatitis A , hemochromatosis , homozygote alpha1 antitrypsin deficiency . Active malignancy . History major organ transplantation exist functional graft . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement . History cardiac arrhythmia , control uncontrolled , include ventricular supraventricular arrhythmia . Pregnant nursing woman . Current diagnosis history cardiac preexcitation syndrome ( e.g . WolffParkinsonWhite ) . Metal implant limb intend administration site . Tattoos , scar , active lesion , rash ≤ 2 cm intend site study treatment . Documentation history seizure within previous 5 year . Pacemaker implant device . Any condition , clinical judgement investigator , would place participant unreasonably increase risk . Receiving investigational agent ≤ 6 month prior Registration . History allergic reaction attribute compound similar chemical biologic composition INO8000 INO9012 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic HCV</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>DNA Vaccine</keyword>
	<keyword>Electroporation</keyword>
</DOC>